Blueprint’s Ayvakit Mastocytosis Results Raise Commercial Uncertainty

 
• By Alaric DeArment
  
Blueprint Medicines announced Phase III data for Ayvakit in indolent systemic mastocytosis • Source: Shutterstock

More from Anticancer

More from Therapy Areas